The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1247-1253

  Stroh, Mark ^a   Palcza, John ^a   McCrea, Jacqueline ^a   Marsilio, Sabrina ^a   Breidinger, Sheila ^a   Panebianco, Deborah ^a   Johnson Levonas, Amy ^a   Kraft, Walter K ^b   Orford, Keith ^a   Murphy, Gail ^a   Agrawal, Nancy ^a   Trucksis, Michele ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug drug interaction; Ketoconazole; Pharmacokinetics; Ridaforolimus; Rifampin

Indexed keywords

KETOCONAZOLE; RIDAFOROLIMUS; RIFAMPICIN; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A; DRUG DERIVATIVE; GLYCOPROTEIN P; RAPAMYCIN;

ABDOMINAL DISTENSION; ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEFECATION DISORDER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; GEOMETRIC MEAN RATIO; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG INTERACTION; HALF LIFE TIME; METABOLISM; MIDDLE AGED;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HALF-LIFE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RIFAMPIN; SIROLIMUS; YOUNG ADULT;

EID: 84862280018     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1819-1     Document Type: Article

References (18)

1. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Exp Opin Invest Drugs 17:1947-1954
2. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428-1434
3. Hartford CM, Ratain MJ (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381-388 (Pubitemid 47414349)
4. Pollock R, Rivera VM, Tang H, Berk L, Gaschet J, Metcalf CA, Clackson T (2003) Cell shrinkage, cell cycle arrest and antiangiogenesis underlie the anti-tumor activity of the mTOR inhibitor AP23573. Clin Cancer Res 9:6176S
5. Rapamune® (sirolimus) (2010) Oral solution and tablets [package insert]. Pzifer Inc., New York
6. Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83-95 (Pubitemid 38283132)
7. Torisel® (temsirolimus concentrate for injection) (2010) [prescribing information]. Pfizer Inc., New York
8. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58 (Pubitemid 28189400)
9. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485 (Pubitemid 24192233)
10. Machavaram KK, Gundu J, Yamsani MR (2006) Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact 22:47-65 (Pubitemid 44784417)
11. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, Wagner JA (2009) Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 49:398-406
12. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C (2002) Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 36:981-985 (Pubitemid 34564379)
13. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45:514-518 (Pubitemid 40562941)
14. Laplanche R, Meno-Tetang GML, Kawai R (2007) Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn 34:373-400 (Pubitemid 46873032)
15. Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H, Sawada Y, Sato H, Takayama T, Sugawara Y, Makuuchi M, Iga T (2004) Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transpl Proc 36:1506-1511 (Pubitemid 38903017)
16. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361-367 (Pubitemid 351171685)
17. Fetterly GJ, Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Bedrosian CL, Rubin EH, Tolcher AW (2008) Pharmacokinetics of oral deforolimus (AP23573, MK-8669) [Abstract 14555]. ASCO annual meeting, vol 26
18. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469 (Pubitemid 36506147)